Virus | Overall prevalence (95% CI) | |||
---|---|---|---|---|
‘Positive’ samples | ‘Quantifiable’ samples | |||
NS | TW | NS | TW | |
EHV-5 | 90.9% (88.9–92.6) | 55.4% (52.3–58.5) | 58.7% (55.6–61.8) | 19.1% (16.7–21.7) |
EHV-2 | 76.4% (73.6–79.0) | 35.4% (32.4–38.5) | 47.7% (44.6–50.8) | 14.6% (12.5–16.9) |
ERBV | 7.8% (6.2–9.6) | 7.8% (6.2–9.6) | 2.1% (1.3–3.2) | 2.9% (2.0–4.1) |
EHV-4 | 6.0% (4.6–7.7) | 3.8% (2.7–5.2) | 1.5% (0.8–2.5) | 1.5% (0.8–2.5) |
EAdV1 | 3.6% (2.5–4.9) | 1.9% (1.1–3.0) | 0.2% (0.0–0.7) | neg. |
EHV-1 | 1.9% (1.1–3.0) | 0.2% (0.0–0.7) | 0.2% (0.0–0.7) | neg. |
ERAV | neg. | 0.2% (0.0–0.7) | neg. | 0.2% (0.0–0.7) |
EAdV2 | neg. | neg. | neg. | neg. |
ECoV | neg. | neg. | neg. | neg. |
EIV | neg. | neg. | neg. | neg. |